Research programme: sigma1 inhibitors - Context Therapeutics/Fred Hutchinson Cancer Research Center/Fondation Synergie Lyon Cancer/Cedars-Sinai Medical Center
Latest Information Update: 28 Sep 2021
At a glance
- Originator Context Therapeutics
- Developer Cedars-Sinai Medical Center; Context Therapeutics; Fondation Synergie Lyon Cancer; Fred Hutchinson Cancer Research Center
- Class Antineoplastics
- Mechanism of Action Sigma-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer; Pulmonary fibrosis
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Prostate-cancer in France
- 28 Sep 2021 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 28 Sep 2021 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in USA